Vascular Biogenics Ltd (VBLT)

[gr8db8]

Key Opinion Leader Ramy Ibrahim, MD from the Parker Institute, will discuss new targets and immunotherapeutic approaches to oncology at a breakfast meeting being held in New York on April 6 at 8 am
==========

Register here: http://lifesci.rampard.com/20170406/reg.jsp

Worth a listen. The guy has AZ connection.

http://www.parkerici.org/media/2016/parker-institute-for-cancer-immunotherapy-adds-key-leader-to-drive-clinical

Parker Institute for Cancer Immunotherapy Adds Key Leader to Drive Clinical Research Efforts

SAN FRANCISCO, June 15, 2016?—?The Parker Institute for Cancer Immunotherapy has recruited Ramy Ibrahim, M.D. as its new Vice President, Clinical Development. Ramy was most recently employed by AstraZeneca where he led the clinical team developing multiple immunotherapies. Ramy Ibrahim is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the National Cancer Institute in Bethesda, MD.

“Ramy has been a pioneer and leader in cancer immunotherapy and will lead the Parker Institute as we grow our collaborative clinical enterprise with our institutional leaders at Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.” said Jeffrey Bluestone, CEO and President, Parker Institute for Cancer Immunotherapy.

Prior to joining the Parker Institute, Ramy served first as Senior Medical Director and most recently, the Clinical Vice President, Immune-Oncology, Global Medicines Development at MedImmune/AstraZeneca where he built and led the clinical team working on the registrational studies both with single drug and combination therapies. As a member of the Bristol Meyers Squib Immuno-oncology program, he served on the BMS Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved Immune Checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PDL1, and CD137 antibody.

Throughout his career, Ramy has been involved with global cancer immunotherapy societies such as Society of Immunotherapy for Cancer (SITC), Ludwig Institute, and the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN).